The data analytics firm smashed Wall Street forecasts for the fourth quarter, reporting a 70% revenue surge to $1.4 billion, driven by explosive growth in its U.S. operations. Its bullish outlook for 2025 further signals resilience amid sector-wide anxieties.
A deep dive into the software company's valuation using a discounted cash flow model suggests its shares may be trading at a significant premium to their estimated intrinsic value.
After a sharp January sell-off, Shopify's stock is hovering near a significant long-term trendline—a level that has preceded notable rallies in the past.
As BHP Group advances plans to create one of the world's first fully autonomous copper mines at Escondida Norte, it simultaneously contends with Chinese import restrictions on its Jimblebar iron ore and ramps up exploration via its 2026 Xplor program, highlighting the complex balancing act facing the global mining giant.
The release of over three million documents by the U.S. Department of Justice has unveiled extensive communications between Jeffrey Epstein and a global network of powerful figures, raising fresh questions about influence, access, and accountability.
Nio's rapid growth and premium positioning make it a compelling story in the EV race, but its massive investment in a proprietary battery-swap network presents a pivotal uncertainty for investors weighing its future.
The Detroit automaker has held preliminary talks with Xiaomi and other Chinese manufacturers about potential joint ventures to build electric vehicles in the United States, a move already drawing sharp criticism from Washington lawmakers.
Major European neobanks like Revolut, Monzo, and bunq are renewing their push for a U.S. banking license, betting on regulatory shifts and market potential. Yet, the path is fraught with complexity, geopolitical uncertainty, and fierce competition.
U.S. equities edged higher Monday, buoyed by a rebound in semiconductor and AI infrastructure stocks, alongside a surge in rare earth companies following a new strategic initiative. Gains were tempered by falling energy shares, cryptocurrency volatility, and ongoing concerns over a partial government shutdown.
Chinese regulators have greenlit the first wave of Nvidia's advanced H200 AI chip orders for major firms including Alibaba and ByteDance, marking a potential turning point for the chipmaker's access to a critical market and fueling optimism for its stock trajectory.
Synthetic biology leader Twist Bioscience reported strong Q1 FY2026 results, with revenue climbing 17% year-over-year to $103.7 million. Management highlighted accelerating demand from AI-powered drug discovery and reiterated its path to adjusted EBITDA breakeven by Q4 FY2026.
As Amgen prepares to report earnings, analysts are divided on the stock's trajectory. While strategic acquisitions and a solid track record fuel optimism, looming competitive pressures and a key pipeline wait temper expectations.
As the wearables market surges, Biolinq CEO Richard Yang positions smart patches as the next evolution, capable of tracking deep biochemical data where watches track surface metrics, with his company's FDA-cleared glucose sensor leading the charge.
Taiwan Semiconductor Manufacturing Company (TSMC), commanding over 70% of the advanced chip foundry market, is accelerating its U.S. manufacturing footprint amid shifting trade policies and sustained explosive financial growth, solidifying its indispensable role.
Amidst market volatility, Microsoft's diversified empire—spanning cloud, AI, productivity, and gaming—positions it as a resilient long-term holding for investors looking beyond short-term fluctuations.
Sony Group's shares have faced significant headwinds, declining over 15% in the past month. As the stock hovers around ¥3,397, analysts are divided on whether this represents a buying opportunity or a sign of deeper challenges in its gaming and sensor divisions.
After years of share price weakness, Immunocore Holdings (IMCR) appears significantly undervalued by traditional metrics. But does the market know something the models don't? We examine the DCF and P/S analyses, the company's unique T-cell receptor platform, and the risks that have kept investors wary.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Investment firm Giverny Capital outlines its rationale for adding Watsco to its portfolio, highlighting a value-oriented strategy as markets remain dominated by AI euphoria. The firm's latest investor letter reveals a challenging quarter of narrow returns.
Investment firm Giverny Capital highlights insurance distributor TWFG as a key holding in its latest letter, revealing a challenging year where its value-focused strategy lagged the AI-fueled market rally.
